Nilotinib Capsules 150 mg
Cipla is recalling Nilotinib Capsules 150 mg due to failed stability specifications observed during long-term testing.
Contact your healthcare provider or pharmacist if you have questions or concerns regarding your medication. Do not stop taking your medication without consulting a medical professional.
Why it was recalled
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
How to identify it
Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each) NDC…
Where it was sold
Distributed in US.
Official source
Other recent recalls from Cipla USA, Inc.
Editorial summary by Recall Canary · last updated 2026-06-05 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification